Journal of Clinical Psychopharmacology

Secondary Logo

Journal Logo

September/October 2023 - Volume 43 - Issue 5

  • Anthony J. Rothschild, MD
  • 0271-0749
  • 1533-712X
  • 6 issues / year
  • Psychiatry 101/155; Pharmacy and Pharmacology 170/279
  • 2.9

Photo -AJ Rothschild, MD in front of medical school.jpgWelcome to the September/October 2023 issue of the Journal of Clinical Psychopharmacology (JCP). There are many articles in this issue that I hope will increase your knowledge and understanding of psychopharmacology.  I would like to highlight a few of them.  In a Commentary titled “Will ChatGP​T3 Substitute for us as Clozapine Experts?"​ (pages 400-402), Drs Jose de Leon and Carlos De Las Cuevas discuss their experiences asking an AI-based tool, ChatGPT3, to write answers to questions regarding clozapine. ChatGPT3 provided nonexistent references using articles from real journals, with real authors, false PubMed identifiers, and false titles.  In my Editorial titled, “Artificial Intelligence and the Journal of Clinical Psychopharmacology" on pages 397-398, I discuss the policies of JCP for authors and reviewers regarding the use of AI.  The Editorial has an accompanying podcast that can be found here​

I am excited to announce that we are bringing back the “Ask the Experts" column.  Please email your questions on clinical psychopharmacology or difficult clinical problems to our office: [email protected]. Details can be found in the Editor's Note​ on page 399.

In a paper titled, “Assessing Adherence to Clozapine: Practical Considerations" on pages 417-421, Flanagan and colleagues studied the incidence of nonadherence to clozapine in samples submitted to a clozapine therapeutic drug monitoring (TDM) service from 1993-2017. They found that while adherence to clozapine may be good in general, tolerance to its potentially fatal cardiovascular effects is easily lost.  They also found that in treatment-resistant schizophrenia, the risk of self-harm increases if clozapine is not taken regularly.  The paper has an accompanying podcast that can be found here​. In another study of the use of clozapine, Grover and colleagues, in a paper titled, “Clinician Reasons for Stopping Clozapine: A Retrospective Cohort Study", (pages 403-406), studied the incidence and reasons clinicians stopped clozapine in patients after initiating treatment. They report clinicians stopped clozapine in only 5.14% of cases, with the most common reasons being blood dyscrasias, poor medication adherence making it challenging to monitor the hemogram, and sedation.

Finally, in a review paper by Uguz and colleagues (pages 434-452) titled “Prophylactic Management of Women With Bipolar Disorder During Pregnancy and the Perinatal Period: Clinical Scenario-Based Practical Recommendations From A Group of Perinatal Psychiatry Authors," the authors provide a clinical update and specific management strategies for women with bipolar disorder during pregnancy and the perinatal period.

And as you will see, there are many interesting Original Contributions, Brief Reports, Review Articles, and Letters to the Editor in the September/October 2023 issue!  And don't forget to check out the podcasts!

Anthony J. Rothschild, MD

Current Issue Highlights

Prophylactic Management of Women With Bipolar Disorder During Pregnancy and the Perinatal Period: Clinical Scenario-Based Practical Recommendations From A Group of Perinatal Psychiatry Authors

Uguz, Faruk; Sharma, Verinder; Boyce, Philip; More

Journal of Clinical Psychopharmacology. 43(5):434-452, September/October 2023.

Duration: 7:44

Much has been written in recent months regarding the growing use of artificial intelligence (AI) in medicine and the potential benefits and risks of its use. In this podcast, Anthony J. Rothschild, MD, Editor-in-Chief of the Journal of Clinical Psychopharmacology, highlights a paper in the journal by Drs. Jose de Leon and Carlos De Las Cuevas that reports their experiment to see how ChatGPT3 would respond to various questions about clozapine metabolism. The generated text proved to be profoundly unreliable.

Dr. Rothschild also discusses his editorial about the journal’s policies regarding use of generative AI by authors and reviewers. Authors must disclose any such use; peer reviewers are prohibited from using AI in conducting their reviews.

Dr. Rothschild’s editorial and the commentary by Drs. De Leon and de Las Cuevas both appear in the September–October 2023 issue of the Journal of Clinical Psychopharmacology.